In short
Omecamtiv mecarbil, also known as CK-1827452, is an investigational medication being studied for its potential benefits in treating heart failure. This cardiac myosin activator works in a unique way by enhancing heart muscle contraction without increasing the heart's oxygen demand. Clinical trials have examined various formulations of this drug—including intravenous infusions and oral capsules—in patients with heart failure, ischemic cardiomyopathy, and angina. These studies have focused on understanding how the drug affects heart function, exercise capacity, and overall cardiac efficiency while monitoring its safety profile and determining optimal dosing regimens.
Key points
- Omecamtiv mecarbil (CK-1827452) is an investigational cardiac myosin activator being studied for heart failure treatment. The clinical trials have evaluated both intravenous and oral formulations in patients with heart failure, ischemic cardiomyopathy, and angina. The drug's unique mechanism aims to improve heart contractility without increasing oxygen demand, potentially offering advantages over traditional heart failure treatments. Studies have measured the drug's effects on exercise capacity, heart function parameters like systolic ejection time and fractional shortening, myocardial efficiency, and pharmacokinetics. Different dosing strategies have been tested to determine optimal treatment regimens and ensure patient safety and tolerance.
What is Omecamtiv Mecarbil?
Omecamtiv mecarbil (also known as CK-1827452) is an investigational medication being studied for the treatment of heart failure. It belongs to a novel class of drugs called cardiac myosin activators. Unlike many existing heart failure medications that affect heart rate or force the heart to contract more strongly, omecamtiv mecarbil works through a unique mechanism that aims to improve the efficiency of the heart's pumping action.
How Does Omecamtiv Mecarbil Work?
Omecamtiv mecarbil works by activating cardiac myosin, a key protein involved in heart muscle contraction. By enhancing the function of this protein, the medication helps the heart contract more effectively without increasing its oxygen demand. This is particularly important because many traditional heart failure medications increase the heart's workload and oxygen consumption, which can sometimes worsen symptoms.
Clinical studies have shown that omecamtiv mecarbil increases the systolic ejection time (the period during which the aortic valve is open and blood is flowing out of the heart) and improves fractional shortening (a measure of how well the heart contracts). These improvements in heart function occur without significantly increasing the heart's oxygen consumption, potentially leading to better myocardial efficiency (the ratio of work performed to oxygen consumed).
Medical Conditions Treated
Omecamtiv mecarbil is being studied primarily for the treatment of heart failure, particularly in patients with reduced ejection fraction (when the heart muscle doesn't contract effectively). The clinical trials have included patients with various forms of heart failure, including:
- Stable heart failure - Heart failure that is not currently worsening but still affects daily activities
- Ischemic cardiomyopathy - Heart failure caused by coronary artery disease and reduced blood flow to the heart muscle
- Left ventricular systolic dysfunction - Weakened pumping ability of the heart's main chamber
Some studies have also specifically examined the medication's effects in patients who have both heart failure and angina pectoris (chest pain caused by reduced blood flow to the heart). This is important because some heart failure medications can worsen angina symptoms.
Formulations and Dosing
Based on the clinical trials, omecamtiv mecarbil has been studied in several different formulations and dosing regimens:
- Intravenous (IV) formulation: Used in shorter-term studies with various dosing protocols, including:
- 2-hour infusions
- 20-hour infusions
- 24-hour infusions
- 72-hour infusions
- Oral formulations: Developed for longer-term use and include:
- Immediate-release (IR) capsules taken three times daily (TID)
- Modified-release (MR) capsules taken twice daily (BID)
The dosing of omecamtiv mecarbil varies across studies, with oral doses ranging from 12.5 mg to 100 mg depending on the formulation and frequency. Intravenous dosing is typically weight-based, with rates adjusted to achieve specific blood concentrations of the medication.
Clinical Research Findings
Multiple clinical trials have investigated the effects of omecamtiv mecarbil on various aspects of heart function and patient outcomes. Key findings from these studies include:
Effects on Exercise Capacity
One important study examined how omecamtiv mecarbil affects exercise tolerance in patients with ischemic cardiomyopathy and angina. This was critical to determine whether the medication might worsen angina symptoms during physical activity. The study used a modified Naughton Exercise Treadmill Test to assess patients' exercise capacity before and during treatment.
Results showed that most patients did not experience worsening of angina symptoms during exercise while taking omecamtiv mecarbil compared to placebo. This suggests that the medication may be suitable for heart failure patients who also have angina, a common comorbidity.
Effects on Heart Function
Several studies have examined how omecamtiv mecarbil affects various measures of heart function:
- Systolic ejection time: The medication consistently increases the time during which the heart is actively pumping blood, with greater increases seen at higher blood concentrations of the drug.
- Fractional shortening: Studies show improvement in this measure of how well the heart contracts.
- Myocardial efficiency: Research suggests that omecamtiv mecarbil may improve the efficiency of the heart by increasing its performance without proportionally increasing oxygen consumption.
- Pressure-volume relationships: Studies have examined how the medication affects the relationship between pressure and volume in the heart chambers.
These findings support the unique mechanism of action of omecamtiv mecarbil, which aims to improve heart function without increasing the heart's workload or oxygen demand.
Safety and Tolerability
The clinical trials have also assessed the safety and tolerability of omecamtiv mecarbil in various patient populations. The studies examined both short-term intravenous administration and longer-term oral dosing.
One study specifically looked at the tolerability of the oral formulation when administered three times daily for up to 7 days in patients with ischemic cardiomyopathy and angina. Another examined the safety of modified-release and immediate-release formulations when taken for 10 days in patients with stable heart failure.
While detailed safety results aren't provided in the available study descriptions, the continued development of the medication suggests that it has demonstrated an acceptable safety profile in these initial studies. As with any investigational medication, ongoing and larger studies will provide more comprehensive information about potential side effects and safety considerations.